Supporting data for " Antibody Responses to COVID-19 Infection and Vaccination"

In light of the COVID-19 pandemic, this study developed and optimized serological assays to assess humoral immunity following SARS-CoV-2 infection and vaccination. Optimized platforms—including IgG ELISA (OD450 was shown in the dataset), surrogate virus neutralization tests (sVNT) (% inhibition was shown in the dataset), and live virus PRNT—enabled quantification of binding and neutralizing antibodies (PRNT90 and PRNT50 were shown in the dataset). Novel ELISAs targeting ORF8 and N-CTD distinguished infection-induced from vaccine-elicited responses. These assays were applied to large-scale sero-epidemiology studies to estimate infection attack rates and vaccine protection. These data were shown in sheets " convalescent cohorts","sVNT prepandemic", "ORF8 Optimization" ,"CTD Optimization".Longitudinal cohort analysis revealed that antibody magnitude and durability correlated with disease severity. Mechanistic modeling using an antibody-secreting cell framework quantified antibody decay dynamics. Comparative vaccine studies showed BNT162b2 elicited higher neutralizing titers than CoronaVac, with heterologous boosting enhancing breadth against Omicron variants. However, neutralization titers did not fully predict protection levels. (Data in sheet " 2 doses", "Low responders", "Cobovax extended""Neutralization against emerging Omicron subvariants and bivalent booster performance highlighted ongoing antigenic drift. This work advances serological surveillance tools and informs vaccine strategy optimization in the evolving COVID-19 landscape. "Data in sheet " BA.1", "BA.2" and "BA45".